AAV 1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington's disease

Gene Therapy

Volumn 23, Issue 3, 2016, Pages 283-295

  Connor, B ^a   Sun, Y ^a   Von Hieber, D ^a   Tang, S K ^a   Jones, K S ^a   Maucksch, C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; NEURON SPECIFIC NUCLEAR PROTEIN; PARVOVIRUS VECTOR; PROTEIN; PROTEIN DARRP32; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BRAIN SIZE; CELL COUNT; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; FUNCTIONAL DISEASE; GENE THERAPY; GENE TRANSFER; GLOBUS PALLIDUS; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROTYPE; SUBSTANTIA NIGRA PARS COMPACTA; THERAPY EFFECT; TRANSGENIC RAT; WILD TYPE; ANIMAL; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; HUNTINGTON DISEASE; PATHOPHYSIOLOGY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUNTINGTON DISEASE; MALE; MODELS, ANIMAL; RATS;

EID: 84960082333     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.113     Document Type: Article

References (49)

1. Ross CA, Tabrizi SJ. Huntingtons disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011; 10: 83-98.
2. Walker FO. Huntington's disease. Lancet. 2007; 369: 218-228.
3. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons disease chromosomes. Cell. 1993; 72: 971-983.
4. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010; 90: 905-981.
5. Vonsattel JP, Keller C, Del Pilar Amaya M. Neuropathology of Huntingtons disease. Handb Clin Neurology. 2008; 89: 599-618.
6. Altar CA. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997; 389: 856-860.
7. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004; 24: 4250-4258.
8. Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 2000; 866: 257-261.
9. Zuccato C. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 2008; 18: 225-238.
10. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 2007; 81: 294-330.
11. Zuccato C. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001; 293: 493-498.
12. Zuccato C. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003; 35: 76-83.
13. Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res. 2005; 52: 133-139.
14. Gauthier LR. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004; 118: 127-138.
15. Colin E. Huntingtin phosphorylation acts as a molecular switch for anterograde/ retrograde transport in neurons. EMBO J. 2008; 27: 2124-2134.
16. Zala D. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet. 2008; 17: 3837-3846.
17. Her LS, Goldstein LS. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci. 2008; 28: 13662-13672.
18. Gines S, Bosch M, Marco S, Gavalda N, Diaz-Hernandez M, Lucas JJ, et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci. 2006; 23: 649-658.
19. Liot G, Zala D, Pla P, Mottet G, Piel M, Saudou F. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci. 2013; 33: 6298-6309.
20. Plotkin JL, Day M, Peterson JD, Xie Z, Kress GJ, Rafalovich I, et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron. 2014; 83: 178-188.
21. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009; 5: 311-322.
22. Strand AD. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci. 2007; 27: 11758-11768.
23. Canals JM. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with encephalinergic neuronal degeneration in Huntington's disease. J Neurosci. 2004; 24: 7727-7739.
24. Pineda JR, Canals JM, Bosch M, Adell A, Mengod G, Artigas F, et al. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J Neurochem. 2005; 93: 1057-1068.
25. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington's disease. Mol Ther. 2004; 9: 682-687.
26. Kells AP, Henry RA, Connor B. AAV-BDNF mediated attenuation of quinolinic acidinduced neuropathology and motor function impairment. Gene Therapy. 2008; 15: 966-977.
27. von Horsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, et al. Transgenic rat model of Huntington's disease. Hum Mol Genet. 2003; 12: 617-624.
28. Carreira J, Jahanshahi A, Zeef D, Kocabicak E, Vlamings R, von Hörsten S, et al. Transgenic rat models of Huntington's disease. In: Geyer MA, Ellenbroek BA, Marsden CA, Barnes ThRE (eds), Current Topics in Behavioral Neurosciences. Springer: Berlin, Heidelberg. 2013, pp 1-13.
29. Nguyen HP, Kobbe P, Rahne H, Worpel T, Jager B, Stephan M, et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum Mol Genet. 2006; 15: 3177-3194.
30. File SE, Lippa AS, Beer B, Lippa MT. Animal tests of anxiety. Curr Protoc Pharmacol 2005, Chapter 5: Unit 5: 38.
31. Kask A, Nguyen HP, Pabst R, von Horsten S. Factors influencing behavior of group-housed male rats in the social interaction test: focus on cohort removal. Physiol Behav. 2001; 74: 277-282.
32. Bohlen M, Cameron A, Metten P, Crabbe JC, Wahlsten D. Calibration of rotational acceleration for the rotarod test of rodent motor coordination. J Neurosci Methods. 2009; 178: 10-14.
33. Deacon RM. Appetitive position discrimination in the T-maze. Nat Protoc. 2006; 1: 13-15.
34. Fielding SA, Brooks SP, Klein A, Bayram-Weston Z, Jones L, Dunnett SB. Profiles of motor and cognitive impairment in the transgenic rat model of Huntington's disease. Brain Res Bull. 2012; 88: 223-236.
35. Bode FJ, Stephan M, Suhling H, Pabst R, Straub RH, Raber KA, et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17β-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet. 2008; 17: 2595-2609.
36. Rios M. Neurotrophins and the regulation of energy balance and body weight. Handb Exp Pharmacol. 2014; 220: 283-307.
37. Liu X, Zhu Z, Kalyani M, Janik JM, Shi H. Effects of energy status and diet on Bdnf expression in the ventromedial hypothalamus of male and female rats. Physiol Behav. 2014; 130: 99-107.
38. Kántor O, Temel Y, Holzmann C, Raber K, Nguyen H-P, Cao C, et al. Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiol Dis. 2006; 22: 538-547.
39. Li XJ, Li S. Influence of species differences on the neuropathology of transgenic Huntington's disease animal models. J Genet Genomics. 2012; 39: 239-245.
40. Li J-Y, Conforti L. Axonopathy in Huntington's disease. Exp Neurol. 2013; 246: 62-71.
41. Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 2011; 198: 252-273.
42. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 2010; 65: 178-190.
43. Nithianantharajah J, Hannan AJ. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience. 2013; 251: 66-74.
44. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-Aspartate receptors via post-synaptic density 95. J Biol Chem. 2001; 276: 24713-24718.
45. Parsons MP, Raymond LA. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron. 2014; 82: 279-293.
46. Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L, et al. Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod. 2007; 22: 995-1002.
47. Borrow AP, Cameron NM. Estrogenic mediation of serotonergic and neurotrophic systems: implications for female mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 54: 13-25.
48. Luine V, Frankfurt M. Interactions between estradiol, BDNF and dendritic spines in promoting memory. Neuroscience. 2013; 239: 34-45.
49. Kells AP, Connor B. AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioning. Neurosci Lett. 2008; 436: 326-330.